Dyslipidemia in Pregnancy: How to Deal

INTRODUCTION

Pregnancy is a unique physiological state characterized by complex hormonal, metabolic, and vascular adaptations that support maternal health while meeting the nutritional and energy demands of the developing fetus. Among these changes, lipid metabolism undergoes a notable shift – from a predominantly anabolic state in early pregnancy to a catabolic state in later gestation. Recent research has significantly advanced our understanding of these metabolic transitions and their clinical implications.^[1,2] During the first trimester, increased insulin sensitivity facilitates fat and glycogen storage. From the second trimester onward, rising levels of placental hormones (human placental lactogen, estrogen, and progesterone) induce insulin resistance and stimulate lipolysis. This metabolic shift ensures adequate substrate delivery to the growing fetus.^[3,4] However, these catabolic changes may worsen preexisting dyslipidemia. The clinical relevance of dyslipidemia during pregnancy extends beyond short-term obstetric complications. Women who experience gestational hyperlipidemia are at increased long-term risk of developing metabolic syndrome, type 2 diabetes, and cardiovascular disease. Furthermore, growing evidence suggests that maternal dyslipidemia may adversely affect fetal health.^[5] In light of rising global trends in maternal age, obesity, and metabolic syndrome, the need to understand and manage dyslipidemia during pregnancy has become increasingly critical. However, therapeutic decision-making remains complex due to concerns about the safety of pharmacologic interventions in this vulnerable population. Consequently, emphasis is placed on pre-conception counseling, routine lipid screening, and targeted lifestyle modifications as foundational strategies. When pharmacologic treatment is considered, it requires a nuanced evaluation of maternal and fetal risks versus potential benefits.

LIPID METABOLISM IN PREGNANCY

Lipid metabolism undergoes distinct physiological adaptations throughout pregnancy. Early pregnancy, particularly the first trimester, represents an anabolic state characterized by increased insulin sensitivity. This promotes maternal lipid accumulation, primarily through adipose tissue deposition, while blood triglyceride (TG) levels remain relatively stable. As pregnancy advances into the second and third trimesters, a catabolic phase emerges. This phase is marked by rising insulin resistance, enhanced lipolysis, and increased hepatic production of TG-rich very low-density lipoproteins (VLDL). During these two trimesters, TG levels typically rise 2.5–3-fold, while low-density lipoproteins-cholesterol (LDL-C) levels increase and shift toward smaller, denser, more atherogenic particles. High-density lipoproteins-cholesterol (HDL-C) initially rises in the second trimester but may decline later in pregnancy.^[6,7] Overall, advancing gestation is associated with increases in total cholesterol and LDL-C by approximately 30– 50%, HDL-C by 20–40%, and TG by 50–100%. These changes reflect critical metabolic adaptations of pregnancy that support placental steroidogenesis, fetal development, and maternal energy demands.^[8]

PATHOPHYSIOLOGY

CLINICAL PATTERNS OF DYSLIPIDEMIA IN PREGNANCY

Dyslipidemia during pregnancy presents in several clinically significant forms, each carrying potential risks for both mother and fetus. One of the most serious conditions is gestational hypertriglyceridemia, defined as TG levels exceeding 500 mg/dL. This severe lipid elevation poses a substantial risk for acute pancreatitis, a complication associated with maternal mortality rates as high as 20%, according to recent case series.^[13] Prompt recognition and management are therefore essential. In women with familial hypercholesterolemia (FH), pregnancy induces lipid changes similar in pattern to those seen in the non-FH population. However, the absolute rise in LDL-C, combined with the preexisting elevations and prolonged exposure, further increases the risk of maternal and fetal atherosclerosis.^[14] Another emerging area of interest is lipoprotein(a) [Lp(a)], whose levels nearly double between 10 and 35 weeks of gestation. Elevated Lp(a) concentrations are observed in approximately 20–30% of pregnant women. Given its association with adverse pregnancy outcomes such as preeclampsia, preterm birth, and low birth weight, some experts suggest routine Lp(a) screening during pregnancy.^[15,16]

ADVERSE PREGNANCY OUTCOMES

Maternal dyslipidemia has been increasingly recognized as a significant contributor to adverse pregnancy outcomes. Recent systematic reviews and meta-analyses have reinforced its association with hypertensive disorders of pregnancy, particularly preeclampsia.^[17-19] It also plays a key role in the development of gestational diabetes mellitus (GDM).^[20,21] Beyond these, dyslipidemia is implicated in preterm birth and abnormal fetal growth patterns. Recent studies from 2024–2025 have shown mixed results, with some linking hypertriglyceridemia to both spontaneous and medically indicated preterm births, as well as low birth weight, increased neonatal intensive care unit admissions, and higher need for phototherapy.^[22-24] Excess maternal lipids – particularly in the context of hypertriglyceridemia and GDM – increase the risk of macrosomia and large-for-gestational-age (LGA) infants. These children are at heightened risk for long-term complications, including obesity and metabolic syndrome.^[25,26] Paradoxically, dyslipidemia is also associated with intrauterine growth restriction. This is believed to result from endothelial dysfunction and placental insufficiency, driven by elevated levels of Lp(a) and oxidized LDL, which impair placental perfusion.^[27-31] Dyslipidemia often persists postpartum, increasing maternal risk for impaired glucose tolerance and metabolic syndrome.^[32-35] Offspring are also affected, as shown by Napoli et al. in the fate of early lesions in children (FELIC) study.^[5] In this study, children born to hypercholesterolemic mothers exhibited early aortic fatty streaks, independent of their postnatal lipid levels. Animal studies further support the concept of fetal programming, showing that maternal high-fat diets can impair neonatal glucose and lipid tolerance.^[26]

SCREENING AND MANAGEMENT

LIFESTYLE AND BEHAVIOURAL INTERVENTIONS

Nutrition and physical activity are key strategies for preventing and managing dyslipidemia during pregnancy. Yet, adherence to optimal dietary regimens remains alarmingly low, with fewer than 0.1% of pregnant women following recommended guidelines.^[42] While there are no pregnancy-specific dietary guidelines for dyslipidemia, current recommendations align with general cardiovascular health principles. These emphasize reducing intake of saturated fats, red meats, processed foods, and trans fats, while promoting consumption of fruits, vegetables, legumes, whole grains, nuts, soy, omega-3 fatty acids, and plant sterols. Evidence from Mediterranean diet (MedDiet) interventions is encouraging. For example, the randomized trial by Melero et al.^[43] demonstrated that initiating a MedDiet supplemented with extra virgin olive oil and nuts before 12 weeks’ gestation improves lipid and glycemic profiles, lowers body mass index (BMI), and reduces long-term risk of metabolic syndrome. Balanced nutrition is especially critical during pregnancy, as overly restrictive diets may impair maternal micronutrient status, whereas excessive caloric intake increases the risk of fetal macrosomia and gestational diabetes. Physical activity complements dietary efforts. Moderate-intensity exercise is encouraged, as it enhances lipid metabolism, improves insulin sensitivity, and reduces gestational weight gain. A recent meta-analysis showed no adverse pregnancy outcomes, with an average weight reduction of 0.7 kg per pregnant woman.^[44] In addition, structured lifestyle and behavioral interventions have been shown to improve glycemic control and hemoglobin A1C levels in women with gestational diabetes.^[45-48] Recommended exercises include walking, swimming, stationary biking, prenatal yoga, and supervised resistance training. However, these activities should be avoided in patients with preterm labor, severe preeclampsia, or placenta previa.

Medium-chain TG (MCTs) offer several potential benefits during pregnancy and in the management of dyslipidemia, though their use requires careful consideration. In pregnancy, MCTs serve as a rapid energy source due to their efficient absorption and hepatic oxidation, which may help meet increased metabolic demands. They also support gut health by reducing pathogenic bacteria, may aid hormonal balance by influencing thyroid and glucose regulation, and could improve lipid metabolism, potentially lowering the risk of gestational dyslipidemia. However, safety data in pregnant populations remain limited, and excessive intake may lead to gastrointestinal discomfort or weight gain, warranting medical consultation before use. In dyslipidemia, MCTs are preferentially oxidized in the liver, reducing fat storage and enhancing satiety, which may indirectly improve lipid profiles.^[49] Evidence from a 2023 literature review and meta-analysis suggests MCTs – particularly caprylic (C8) and capric (C10) acids – can significantly reduce TG and modestly affect LDL and HDL levels when incorporated into a controlled diet.^[50] Clinically, MCTs may be considered a non-pharmacological adjunct in patients with metabolic syndrome or obesity, and while their role in pregnancy-related dyslipidemia remains underexplored, they may offer a safer alternative to long-chain fats in select high-risk cases.

PHARMACOLOGICAL THERAPY

Pharmacological management of dyslipidemia in pregnancy is challenging due to the need to balance maternal cardiovascular health with fetal safety. Most clinical trials exclude pregnant women, resulting in limited high-quality safety data. Consequently, guidelines remain conservative, contraindicating most lipid-lowering agents during pregnancy and lactation.^[3,37-39] However, therapeutic intervention may be necessary for women with severe hypercholesterolemia or hypertriglyceridemia, especially those with FH or at risk of pancreatitis.

SPECIAL POPULATIONS

POSTPARTUM EFFECTS AND LONG-TERM IMPLICATIONS

Pregnancy functions as a physiological “stress test” for maternal cardiovascular health, revealing underlying metabolic vulnerabilities. Gestational dyslipidemia, characterized by abnormal lipid levels during pregnancy, serves as a predictor of long-term complications, including persistent dyslipidemia,^[34,35] metabolic syndrome, type 2 diabetes,^[32,33] and elevated lifetime cardiovascular disease risk.^[7,34]. Although lipid levels typically normalize within 6–12 weeks postpartum, women with FH or pre-existing dyslipidemia may experience sustained elevations, warranting repeat lipid profiling and consideration of pharmacologic therapy after breastfeeding concludes.^[88] Longitudinal studies affirm the heightened cardiovascular risk in these women, prompting recommendations for closer surveillance and annual cardiovascular risk assessments.^[89] Breastfeeding offers metabolic benefits, including enhanced lipid mobilization and improved maternal lipid profiles. However, most lipid-lowering agents – including statins, ezetimibe, PCSK9 inhibitors, and newer therapies – are contraindicated during lactation due to potential transmission through breast milk. BASs are a safe alternative as they are not systemically absorbed.^[51,90] Offspring born to mothers with dyslipidemia are also at increased risk for obesity, insulin resistance, and metabolic syndrome, with intrauterine programming contributing to early atherosclerotic changes. Studies underscore the intergenerational impact of maternal metabolic health during pregnancy,^[5,26] and early lifestyle interventions in children may help mitigate these long-term risks. A brief overview of management strategies for dyslipidemia in pregnancy is depicted in Figure 1.

Close

Figure 1:

Image depicting management of dyslipidemia in pregnancy. (BAS: Bile acid sequestrants)

Export to PPT

FUTURE DIRECTIONS AND CONCLUSION

Dyslipidemia during pregnancy presents a physiological paradox: while vital for fetal development, excessive levels can become pathological, contributing to adverse maternal and fetal outcomes. Lately increased incidence of obesity, diabetes, and metabolic syndrome has made this a bigger problem. The lack of robust guidelines, driven by the exclusion of pregnant women from clinical trials, forces reliance on extrapolated data from animal models and observational studies. Clinicians must carefully balance maternal cardiovascular risk reduction with fetal safety. There is an urgent need for large-scale prospective studies to define safe lipid thresholds during pregnancy and to clarify their long-term implications for both maternal and offspring health. While universal lipid screening in pregnancy remains debated, broader testing could enable early detection of FH and prevent downstream complications.^[41] Promising therapies like inclisiran—a biannual siRNA targeting PCSK9 with 40–50% LDL-C reduction,^[71] and TG-lowering agents such as ApoC3 inhibitors (olezarsen) and ANGPTL3 inhibitors (evinacumab)^[91,92] offer future potential. However, the safety of these drugs in pregnancy has not been established. Similarly, emerging gene editing and RNA-based therapies may transform care of inherited dyslipidemias outside of pregnancy but are currently contraindicated during gestation. As most of these medications are avoided in pregnancy, lifestyle intervention remains the cornerstone of management. This should be supported by pre-conception counseling and selective lipid screening. Approved therapies during pregnancy are limited to BASs, omega-3 fatty acids, and LA. Statins and fibrates may be cautiously considered under specialist supervision in high-risk cases. While global guidelines broadly emphasize lifestyle modification and discontinuation of most lipid-lowering drugs during pregnancy, they differ in recommendations for screening and therapeutic strategies. Bridging these gaps through future research, particularly in areas such as universal screening, long-term maternal-offspring outcomes, and safe novel therapies, is essential.

Ultimately, pregnancy offers a unique opportunity to identify women with dyslipidemia at increased risk for cardiovascular disease. Implementing early preventive strategies during this period has the potential to reduce the burden of cardiovascular disease across generations.

DYSLIPIDEMIA IN PREGNANCY: HOW TO DEAL? – CURRENT RECOMMENDATIONS ACCORDING TO VARIOUS INTERNATIONAL BODIES

DYSLIPIDEMIA IN PREGNANCY: HOW TO DEAL? – INDIAN SCENARIO AND EVIDENCE

Several Indian studies have underscored the prevalence and implications of dyslipidemia during pregnancy, with Chhabra et al. (2013) reporting elevated TG and LDL-C levels in women with preeclampsia compared to normotensive controls,^[97] Mandal et al. (2016) demonstrating that abnormal lipid profiles in the second trimester predicted GDM,^[98] Gupta et al. (2020) observing hypertriglyceridemia in approximately 20% of urban Indian pregnant women associated with macrosomia and preterm birth,^[99] and Kumari et al. (2021) noting that lipid abnormalities persisted postpartum in some women, indicating a higher long-term cardiometabolic risk.^[100] While international guidelines such as those from the AHA and ACOG do not recommend routine lipid screening for all pregnant women, they advise targeted screening in high-risk cases.^[101,102] In the Indian context, selective screening is particularly warranted for women with a family history of premature cardiovascular disease, pre-pregnancy obesity (BMI >25 kg/m²), prior GDM or preeclampsia, or a history of severe hypertriglyceridemia or pancreatitis. Management should primarily emphasize nonpharmacological measures, including a balanced, fiber-rich diet consistent with traditional Indian dietary patterns, moderate physical activity, and nutritional supplementation with omega-3 fatty acids from fish or flaxseed oil. Pharmacologic therapy remains limited: statins are contraindicated,^[6] fibrates and niacin are generally avoided unless in life-threatening cases, insulin may indirectly improve dyslipidemia in GDM, and BASs such as cholestyramine are considered safe but have limited use due to gastrointestinal side effects. Monitoring lipid profiles in high-risk women at booking and again in the second trimester is advisable, with postpartum follow-up strongly recommended as persistent dyslipidemia may predict future cardiovascular disease.^[100] Major challenges in India include low awareness among healthcare providers, limited routine lipid testing, socioeconomic constraints affecting lifestyle modification, and widespread vegetarianism restricting omega-3 intake from marine sources. Overall, dyslipidemia in pregnancy should be recognized as a clinically significant risk factor in India, warranting selective screening, emphasis on lifestyle-based management, postpartum surveillance, and the development of India-specific guidelines integrated into national maternal health programs.

CONCLUSION

Dyslipidemia in pregnancy represents a physiological paradox in which gestational rises in cholesterol and triglycerides are necessary to support placental steroidogenesis and fetal growth, yet excessive or prematurely elevated lipid levels contribute to preeclampsia, gestational diabetes, preterm birth, macrosomia, fetal growth restriction, and adverse long-term cardiometabolic outcomes in both mother and offspring. These risks are accentuated in women with pre-existing dyslipidemia, familial hypercholesterolemia, severe hypertriglyceridemia, or coexisting cardiometabolic disorders, underscoring the need to treat pregnancy as a cardiometabolic “stress test” that unmasks latent vascular vulnerability and predicts future cardiovascular disease.

An individualized, risk-based approach that starts with preconception counselling, selective lipid screening in high-risk women, and intensive lifestyle optimization remains the cornerstone of management. Heart-healthy, culturally appropriate dietary patterns emphasizing reduced saturated and trans fats, adequate omega-3 intake, weight control, and moderate physical activity should be prioritized, with pharmacologic therapy reserved for selected situations in which maternal benefit clearly outweighs fetal risk. At present, bile acid sequestrants, omega-3 fatty acids, and lipoprotein apheresis constitute the principal evidence-supported options during pregnancy, whereas statins and fibrates may be cautiously considered only in very high-risk women under specialist supervision and shared decision-making.

Postpartum follow-up with lipid reassessment at 6–12 weeks is crucial to distinguish physiological normalization from persistent dyslipidemia, enabling timely initiation or intensification of long-term preventive strategies in women at elevated lifetime cardiovascular risk. Recognition of the intergenerational impact of maternal dyslipidemia, including early atherogenesis and future obesity and metabolic syndrome in offspring, further strengthens the case for coordinated obstetric–cardiology care, structured postpartum surveillance, and family-based lifestyle interventions. Future research must focus on defining pregnancy-specific lipid thresholds, clarifying the safety of emerging lipid-lowering agents, and developing context-specific guidelines, particularly for resource-constrained settings, so that pregnancy can be fully leveraged as an opportunity to interrupt the cycle of dyslipidemia and cardiovascular disease across generations.